| 000 | 01255 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513112952.0 | ||
| 264 | 0 | _c19970407 | |
| 008 | 199704s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(05)61562-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAndersson, P B | |
| 245 | 0 | 0 |
_aHow should we proceed with disease-modifying treatments for multiple sclerosis? _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMar 1997 |
||
| 300 |
_a586-7 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Journal Article | ||
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInterferon beta-1a |
| 650 | 0 | 4 | _aInterferon beta-1b |
| 650 | 0 | 4 |
_aInterferon-beta _xtherapeutic use |
| 650 | 0 | 4 |
_aMultiple Sclerosis _ximmunology |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 700 | 1 | _aWaubant, E | |
| 700 | 1 | _aGoodkin, D E | |
| 773 | 0 |
_tLancet (London, England) _gvol. 349 _gno. 9052 _gp. 586-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(05)61562-0 _zAvailable from publisher's website |
| 999 |
_c9045771 _d9045771 |
||